Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pediatr Endocrinol Metab ; 36(6): 517-522, 2023 Jun 27.
Artigo em Inglês | MEDLINE | ID: mdl-37114861

RESUMO

OBJECTIVES: The COVID-19 pandemic had profound effect on physical and mental health. Stress was due physical inactivity, increased screen time, social isolation, fear of illness/death, as well as relative lack of resources including healthy food and finances. These stressors may be associated with an increase in idiopathic central precocious puberty (ICPP). The aim of the study was to assess the incidence of ICPP in females during the COVID-19 pandemic and compare biochemical and radiological parameters of females diagnosed in the previous two years, looking at associations among BMI, screen time, isolation, and stress in relation to the development of early puberty. METHODS: A retrospective chart review was performed of females diagnosed with ICPP. We divided subjects into a pandemic group and pre-pandemic group based on time of diagnosis. We compared anthropometric, serologic and radiologic data between the two groups. To assess psychosocial stress, we reviewed a COVID-19 impact survey which was administered to families at our endocrine clinic. RESULTS: There were a total of 56 subjects in the study; 23 subjects in the pre-pandemic group and 33 in the pandemic group. The pandemic cohort had significantly higher estradiol and LH levels and larger ovarian volumes. Survey results showed parental report of stress was moderate in 38 % of subjects and severe in 25 % of parents. In children, reported stress was moderate in 46 % of subjects. CONCLUSIONS: As puberty is influenced by exogenous factors including weight gain and psychosocial stress, we suspect that the environmental stress surrounding the pandemic influenced the increase in ICPP.


Assuntos
COVID-19 , Puberdade Precoce , Feminino , Humanos , Criança , Puberdade Precoce/diagnóstico , Puberdade Precoce/epidemiologia , COVID-19/epidemiologia , Pandemias , Estudos Retrospectivos , Cidade de Nova Iorque , Teste para COVID-19
2.
Int J Surg Case Rep ; 39: 36-38, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28802163

RESUMO

INTRODUCTION: Gastrointestinal leiomyomas are often clinically silent until they bleed or grow large enough to cause local mass effect. PRESENTATION OF CASE: We report the unique case of an otherwise healthy 69-year-old male who developed a small bowel obstruction secondary to a mobile small intestinal leiomyoma. During initial evaluation, computed tomography did not demonstrate the cause of obstruction. Because of worsening clinical status with conservative management, the patient required emergency laparotomy. Operative findings were significant for an intraluminal leiomyoma that had detached from its pedicle, traveled to the tight lumen of the distal ileum and acted as an obstructive "bezoar" composed of native tissue. Removal of the mass resulted in rapid metabolic stabilization and relief of symptoms. DISCUSSION: This case report illustrates the complexity of diagnosing obstruction secondary to intraluminal native tissue. Clinicians must be aware that such masses may clinically present as but not have corresponding radiographic stigmata of typical bezoars. CONCLUSION: In the absence of clear clinical or radiographic etiology for obstruction, developing a heightened degree of suspicion for native tissue "bezoar" may allow quick and appropriate management of similar cases and limit complications associated with prolonged obstruction. To our knowledge, this is the first reported case of mobile intraluminal leiomyoma causing small bowel obstruction.

3.
Menopause ; 21(6): 612-23, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24281237

RESUMO

OBJECTIVE: This study aims to determine the dose-dependent effects of testosterone on sexual function, body composition, muscle performance, and physical function in hysterectomized women with or without oophorectomy. METHODS: Seventy-one postmenopausal women who previously underwent hysterectomy with or without oophorectomy and had total testosterone levels less than 31 ng/dL or free testosterone levels less than 3.5 pg/mL received a standardized transdermal estradiol regimen during the 12-week run-in period and were randomized to receive weekly intramuscular injections of placebo or 3, 6.25, 12.5, or 25 mg of testosterone enanthate for 24 weeks. Total and free testosterone levels were measured by liquid chromatography-tandem mass spectrometry and equilibrium dialysis, respectively. The primary outcome was change in sexual function measured by the Brief Index of Sexual Functioning for Women. Secondary outcomes included changes in sexual activity, sexual distress, Derogatis Interview for Sexual Functioning, lean body mass, fat mass, muscle strength and power, and physical function. RESULTS: Seventy-one women were randomized; five groups were similar at baseline. Sixty-two women with analyzable data for the primary outcome were included in the final analysis. The mean on-treatment total testosterone concentrations were 19, 78, 102, 128, and 210 ng/dL in the placebo, 3-mg, 6.25-mg, 12.5-mg, and 25-mg groups, respectively. Changes in composite Brief Index of Sexual Functioning for Women scores, thoughts/desire, arousal, frequency of sexual activity, lean body mass, chest-press power, and loaded stair-climb power were significantly related to increases in free testosterone concentrations; compared with placebo, changes were significantly greater in women assigned to the 25-mg group, but not in women in the lower-dose groups. Sexual activity increased by 2.7 encounters per week in the 25-mg group. The frequency of androgenic adverse events was low. CONCLUSIONS: Testosterone administration in hysterectomized women with or without oophorectomy for 24 weeks was associated with dose and concentration-dependent gains in several domains of sexual function, lean body mass, chest-press power, and loaded stair-climb power. Long-term trials are needed to weigh improvements in these outcomes against potential long-term adverse effects.


Assuntos
Androgênios/administração & dosagem , Histerectomia , Sexualidade/efeitos dos fármacos , Testosterona/análogos & derivados , Testosterona/sangue , Androgênios/efeitos adversos , Nível de Alerta/efeitos dos fármacos , Composição Corporal/efeitos dos fármacos , Relação Dose-Resposta a Droga , Feminino , Humanos , Pessoa de Meia-Idade , Força Muscular/efeitos dos fármacos , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/fisiologia , Ovariectomia , Pós-Menopausa , Comportamento Sexual/efeitos dos fármacos , Testosterona/administração & dosagem , Testosterona/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...